May 24th 2023
Bill 1196 / Assembly Bill 1673 aims to improve access to precision medicine for patients with cancer in New York by requiring all state-regulated health plans to cover biomarker testing when it is supported by medical and scientific evidence.
February 3rd 2023
August 26th 2022
July 11th 2022
Challenges in the Field of Hereditary Breast CancerAugust 8th 2014
Claudine Isaacs, MD, professor, medical Director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses some of the challenges physicians are facing in the field of hereditary breast cancer.
A New Concept to Broaden Access to Molecular TestingAugust 6th 2014
During a 2013 discussion on treating NSCLC, a group of oncologists were asked what share of cancer patients have access to molecular testing. The answers varied: One said he guessed 40% to 50%, another said "a large minority."
Validating Gene Signatures in mCRPCMay 6th 2014
William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the process of validating a whole-blood prognostic signature in metastatic castration-resistant prostate cancer (mCRPC).
A Next-Generation Sequencing-Based Assay for Hematologic MalignanciesMay 1st 2014
Marcel R.M. van den Brink, MD, PhD, from Memorial Sloan Kettering Cancer Center, describes a novel CLIA-certified next-generation sequencing-based assay for hematologic malignancies.
Combining and Sequencing Agents with Immunotherapies in Prostate CancerApril 23rd 2014
Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, discusses combining and sequencing agents with immunotherapies for the treatment of prostate cancer.
The Outlook for BRCA Genetic Testing and CounselingApril 2nd 2014
The US Supreme Courtâ€™s landmark decision last June, mandating that an individualâ€™s genes cannot be patented, transformed the genetic testing landscape and opened the marketplace to a host of new and complicated testing options.
Findings From Next-Generation Sequencing Offer Promise for New Breast Cancer TherapiesMarch 24th 2014
The most promising novel therapeutics in development for patients with breast cancer focus primarily on targeting activating mutations in combinations that are based on findings from next-generation sequencing.
Developing Next-Generation Anti-Androgen Therapies for CRPCMarch 21st 2014
Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, discusses next-generation anti-androgen therapies for patients with castration-resistant prostate cancer
AR Findings Highlight Detailed Tumor-Profiling StudyMarch 7th 2014
A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression.
Plasma Testing Approaches for Lung CancerOctober 7th 2013
Tony S.K. Mok, BMSc, MD, FRCPC, professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong, China, discusses different plasma testing approaches for patients with lung cancer.